DK1701722T3 - N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidin-2-methansulfonsyresalt - Google Patents

N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidin-2-methansulfonsyresalt

Info

Publication number
DK1701722T3
DK1701722T3 DK05817697T DK05817697T DK1701722T3 DK 1701722 T3 DK1701722 T3 DK 1701722T3 DK 05817697 T DK05817697 T DK 05817697T DK 05817697 T DK05817697 T DK 05817697T DK 1701722 T3 DK1701722 T3 DK 1701722T3
Authority
DK
Denmark
Prior art keywords
benzamidine
pentoxy
thiazol
phenoxy
isopropyl
Prior art date
Application number
DK05817697T
Other languages
English (en)
Inventor
Eun Hee Cho
Jei Man Ryu
Jin Soo Lee
Dong Hyuk Shin
Seung Kyoo Seong
Soon Ki Cho
Chan Seok Jeon
Young Goo Jin
Ki Young Lee
Se Hyun Jung
Seok Hoon Ahn
Original Assignee
Dong Wha Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36498212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1701722(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dong Wha Pharm Co Ltd filed Critical Dong Wha Pharm Co Ltd
Application granted granted Critical
Publication of DK1701722T3 publication Critical patent/DK1701722T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DK05817697T 2004-11-23 2005-11-22 N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidin-2-methansulfonsyresalt DK1701722T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20040096390 2004-11-23
PCT/KR2005/003934 WO2006057501A1 (en) 2004-11-23 2005-11-22 N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt

Publications (1)

Publication Number Publication Date
DK1701722T3 true DK1701722T3 (da) 2010-01-11

Family

ID=36498212

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05817697T DK1701722T3 (da) 2004-11-23 2005-11-22 N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidin-2-methansulfonsyresalt

Country Status (19)

Country Link
US (2) US20070254930A1 (da)
EP (2) EP1701722B1 (da)
JP (2) JP4773456B2 (da)
KR (2) KR100716389B1 (da)
CN (3) CN101693029B (da)
AT (1) ATE445397T1 (da)
AU (2) AU2005300239B2 (da)
BR (2) BRPI0514386B8 (da)
CA (2) CA2552766C (da)
DE (1) DE602005017118D1 (da)
DK (1) DK1701722T3 (da)
ES (1) ES2333739T3 (da)
HK (1) HK1094530A1 (da)
IL (2) IL180985A (da)
NZ (1) NZ555725A (da)
PT (1) PT1701722E (da)
RU (1) RU2361867C2 (da)
WO (2) WO2006057507A1 (da)
ZA (2) ZA200700485B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080200526A1 (en) * 2004-07-05 2008-08-21 Jin Soo Lee Composition for the Prevention and Treatment of Allergic Inflammatory Disease
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
US20070254930A1 (en) * 2004-11-23 2007-11-01 Dong Wha Pharm. Ind. Co., Ltd. Oral Preparation Having Improved Bioavailability
US8039635B2 (en) 2007-04-19 2011-10-18 Dong Wha Pharmaceutical Co., Ltd. N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl) phenoxy]pentoxy} benzamidine 2 ethansulfonic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same
JP5656258B2 (ja) * 2011-03-09 2015-01-21 塩野義製薬株式会社 ガランタミンを含有する口腔内崩壊錠剤
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
JP6292744B2 (ja) * 2012-09-19 2018-03-14 富士カプセル株式会社 医薬品組成物
JP6379044B2 (ja) * 2013-01-31 2018-08-22 沢井製薬株式会社 テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤
TWI721954B (zh) 2014-08-28 2021-03-21 日商衛材R&D企管股份有限公司 高純度喹啉衍生物及其生產方法
RU2017128583A (ru) 2015-02-25 2019-03-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ ослабления горечи хинолинового производного
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
EP3290037A4 (en) 2015-04-28 2019-01-23 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
BR112020003380A2 (pt) * 2017-08-18 2020-08-25 Abbvie Inc. formulações farmacêuticas para o tratamento de endometriose, miomas uterinos, síndrome do ovário policístico ou adenomiose
KR102276547B1 (ko) * 2020-09-04 2021-07-13 주식회사유한양행 오메프라졸, 에스오메프라졸 또는 이의 약제학적으로 허용가능한 염을 포함하는 정제 형태의 약학 조성물 및 이의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
WO1989006959A1 (en) * 1988-02-03 1989-08-10 Yoshitomi Pharmaceutical Industries, Ltd. Pharmaceutical composition having improved releasability
PA8441701A1 (es) * 1996-11-26 2000-05-24 Pfizer Sales dimesilato de los ligandos del neuropeptido y
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
CN1572882A (zh) * 1999-10-28 2005-02-02 三共株式会社 苯甲脒衍生物
KR100454767B1 (ko) * 2001-07-19 2004-11-03 동화약품공업주식회사 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도
KR100789567B1 (ko) * 2001-11-06 2007-12-28 동화약품공업주식회사 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도
ES2448501T3 (es) * 2002-03-06 2014-03-14 Effrx Pharmaceuticals Sa Composiciones efervescentes que comprenden bisfosfonatos
BR0309188A (pt) * 2002-04-12 2005-02-09 Pfizer Compostos pirazolo como agentes antiinflamatórios e analgésicos
US7157100B2 (en) 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
WO2004082692A1 (ja) * 2003-03-18 2004-09-30 Kowa Co., Ltd. 制酸剤組成物
US20070254930A1 (en) * 2004-11-23 2007-11-01 Dong Wha Pharm. Ind. Co., Ltd. Oral Preparation Having Improved Bioavailability

Also Published As

Publication number Publication date
BRPI0514386B8 (pt) 2021-05-25
KR20060057514A (ko) 2006-05-26
EP1701722B1 (en) 2009-10-14
KR20060057511A (ko) 2006-05-26
EP1701722A4 (en) 2007-05-16
RU2361867C2 (ru) 2009-07-20
ATE445397T1 (de) 2009-10-15
CA2552766C (en) 2010-08-17
ES2333739T3 (es) 2010-02-26
KR101047042B1 (ko) 2011-07-06
CN101056658A (zh) 2007-10-17
BRPI0514386B1 (pt) 2021-02-09
IL180985A0 (en) 2007-07-04
JP2008520655A (ja) 2008-06-19
ZA200700485B (en) 2007-11-28
KR100716389B1 (ko) 2007-05-11
IL180985A (en) 2012-02-29
AU2005300239A1 (en) 2006-07-06
NZ555725A (en) 2008-07-31
BRPI0517396A (pt) 2008-10-14
EP1701722A1 (en) 2006-09-20
HK1094530A1 (en) 2007-04-04
JP2008508264A (ja) 2008-03-21
CA2585003A1 (en) 2006-06-01
BRPI0514386A (pt) 2008-06-10
AU2005307994B2 (en) 2009-07-23
US20070254930A1 (en) 2007-11-01
EP1814593A1 (en) 2007-08-08
JP4773456B2 (ja) 2011-09-14
JP4774053B2 (ja) 2011-09-14
IL182647A (en) 2011-04-28
CN101693029A (zh) 2010-04-14
ZA200704236B (en) 2008-11-26
WO2006057507A1 (en) 2006-06-01
RU2007123614A (ru) 2008-12-27
CN1905871A (zh) 2007-01-31
CN101693029B (zh) 2011-11-02
US20090176846A1 (en) 2009-07-09
EP1814593A4 (en) 2012-09-05
WO2006057501A1 (en) 2006-06-01
PT1701722E (pt) 2009-12-10
CA2585003C (en) 2010-08-17
CN100574756C (zh) 2009-12-30
CN1905871B (zh) 2010-07-07
IL182647A0 (en) 2007-07-24
CA2552766A1 (en) 2006-06-01
DE602005017118D1 (de) 2009-11-26
AU2005307994A1 (en) 2006-06-01
AU2005300239B2 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
ATE445397T1 (de) N-hydroxy-4-ä5-ä4-(5-isopropyl-2-methyl-1,3- thiazol-4-yl)phenoxyüpentoxyübenzamidin 2 methansulfonsauresalz
WO2003097622A3 (en) Synthesis of 2-alkylcysteines, 2-(hydroxylated phenyl)-4-alkylthiazoline-4-carboxylic acids and derivatives thereof
PE20070351A1 (es) N-[2-[haloalcoxi)fenil]heteroarilcarboxamidas fungicidas
UA92354C2 (en) Amino acid salts of rosiglitazone
CY1107238T1 (el) Παρασκευη μιας πολυμορφικης μορφης ενος παραγωγου θειαζολιδινοδιονης
JP2010529147A5 (da)
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
MX2009010491A (es) Derivado heterociclico de 5 miembros y su uso para propositos medicos.
TW200633981A (en) Process for the preparation of a 2-ethylaminopyridine derivative
WO2006003471A3 (en) Process for the preparation of pramipexole by chiral chromatography
WO2008104847A3 (en) Processes for the preparation of pramipexole and salts thereof
WO2011021214A3 (en) Improved process for preparing (s)-2-amino-4, 5, 6, 7-tetrahydro-6-(propylamino)benzothiazole and its dhtydrochloride monohydrate
ATE414080T1 (de) Synthese von antidiabetischen rosiglitazonderivaten
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner
MX2019007327A (es) Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.
BRPI0607085A2 (pt) derivados de oximas heterocìclicos, o respectivo processo de preparação e a respectiva utilização como agentes hipoglicemiantes e hipolipemiantes
WO2008133128A1 (ja) 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途
WO2009012201A3 (en) Process for the preparation of trifluoroalkyl-phenyl and heterocyclic sulfonamides
NZ598754A (en) Therapeutic agent for anxiety disorders
WO2005012273A3 (en) Process for the preparation of substituted thiazoles
EP2146974A4 (en) SALT OF N-HYDROXY-4- {5- [4- (5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL) PHENOXY] PENTOXY} BENZAMIDINE 2-ETHANESULPHONIC ACID, ITS PREPARATION METHOD AND COMPOSITION PHARMACEUTICAL COMPRISING IT
WO2005021542A3 (en) Process for the preparation of pioglitazone
EA200300230A1 (ru) Тартратная соль производного тиазолидиндиона
ATE425162T1 (de) Thiazolderivate als npy-antagonisten
AU2003269479A1 (en) Phosphoric acid salt of 5-((4-(2-(5-ethyl-2-pyridinyl) ethoxy) phenyl) methyl)-2, 4-thiazolidinedione